Introduction & Objective: Public health measures, especially vaccination, are important for COVID-19 risk reduction. Population level vaccine uptake in people with diabetes is understudied. We assessed COVID-19 vaccine uptake among adults with and without diabetes and the factors associated with vaccination.

Methods: This retrospective, population-based cohort study included adults (18+ years) living in Alberta, Canada on December 14, 2020, the date of vaccine availability. Diabetes status was determined using a validated algorithm between April 1, 2002 and December 14, 2020. All individuals were followed until March 31, 2022. The primary outcome was full vaccination as defined by the manufacturer. Descriptive statistics were used to compare vaccination status among people with and without diabetes and multivariate logistic regression assessed the factors associated with full vaccination adjusting for age group, sex, diabetes status, material deprivation, urban/rural residence, and comorbidities (Charlson Comorbidity Index (CCI) score).

Results: We identified 3,779,733 adults (49.7% female, mean age 46.8 ± 17.8 years) with 9.8% having diabetes. Overall, 75.5% of the total cohort were fully vaccinated. A higher proportion of people with diabetes, compared to those without, were fully vaccinated (83.9% vs. 74.6%, p<0.001). The presence of diabetes (aOR 1.48; 95% CI 1.46-1.49), female sex (aOR 1.20; 95% CI 1.91-1.21), and CCI score >1 (aOR 1.67; 1.66-1.68) were associated with being fully vaccinated, whereas the age group of ≥ 75 years (aOR 0.84; 95% CI 0.83-0.86), rural residence (aOR 0.60; 95% CI 0.60-0.60) and higher material deprivation (aOR 0.88; 95% CI 0.87-0.89) were associated with lower vaccination.

Conclusions: People with diabetes had high COVID-19 vaccination uptake and were more likely than the general population to be fully vaccinated. We also identified several key factors associated with lower uptake highlighting the need for understanding facilitators of vaccination.

Disclosure

S. Butalia: None. B.R. Shah: None. R.J. Sigal: Research Support; Lexicon Pharmaceuticals, Inc., Bayer Inc., Novo Nordisk. J.L. Benham: None. B. Wicklow: None. C.H. Yu: None. K. Dasgupta: None. S. Amed: None. C. Constantinescu: Research Support; Pfizer Inc. Other Relationship; Sta HealthCare Communications, Canadian Research Network. M. Chu: None. P. Kaul: None.

Funding

Canadian Institutes of Health Research (CIHR) 483868

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.